The Correlation and Mechanistic Study of GGCX Gene With Prognosis in Acute Ischemic Stroke

NCT07269288 | Not Yet Recruiting

• 2 other identifiers: 20250172024PSPT0905100
• Study Type: observational
• Target: 1,500
• Locations: 1 country
• Sites: 1

Brief Summary

This observational study aims to investigate the impact of GGCX gene mutations and GGCX levels on stroke prognosis in patients with ischemic stroke, as well as their correlation. The main issues are: What is the relationship and potential mechanism between GGCX gene mutations and their expression levels and the composite prognosis of recurrence, death, and bleeding events in patients with ischemic stroke? Collect blood samples from enrolled ischemic stroke patients for genetic testing, and conduct follow-up visits at 3, 6, and 12 months after discharge to evaluate clinical prognosis outcomes. This will answer questions about the relationship and mechanism between GGCX gene and patient prognosis.

Conditions

Acute Ischemic Stroke

Keywords

Stroke

Outcome Measures

Primary Outcomes (1)

• Evaluate the recurrence, death, and bleeding events of stroke in the research subjects

  Including recurrent ischemic stroke events; Death events include hemorrhagic death, vascular death, and acute myocardial infarction events; Intracranial or other bleeding events (refer to the International Classification of Bleeding Events ICD-10 code).

  Follow up will be conducted at 3 months, 6 months, and 12 months after the patient's discharge, and the main outcome events mentioned above will be evaluated.

Study Arms (1)

Acute Ischemic Stroke Group

These subjects were acute ischemic stroke patients who had been followed up for 3-12 months after discharge.

Combination Product: Usually, all enrolled patients with acute ischemic stroke will receive routine medication and/or surgical treatment according to clinical diagnosis and treatment protocols.

Interventions

Usually, all enrolled patients with acute ischemic stroke will receive routine medication and/or surgical treatment according to clinical diagnosis and treatment protocols. COMBINATION_PRODUCT

The conventional drug therapy includes anticoagulant, antiplatelet, antihypertensive and other drugs. The surgical therapy includes AIS intravenous thrombolysis or endovascular therapy.

Acute Ischemic Stroke Group

Eligibility Criteria

• Age: 18 Years - 85 Years
• Sex: all
• Healthy Volunteers: Yes
• Age Groups: Adult (18-64), Older Adult (65+)
• Sampling Method: Probability Sample

Study Population

This study will be conducted in six hospitals (centers) across the country, namely Xi'an Jiaotong University First Affiliated Hospital, Shandong Weifang Second People's Hospital, Shandong Linshu People's Hospital, Hunan Second People's Hospital (Hunan Brain Hospital), and Nantong First People's Hospital.

You may qualify if:

• Aged between 18 and 85 years.
• Diagnosed with ischemic stroke (in accordance with the "Chinese Guidelines for Diagnosis and Treatment of Acute Ischemic Stroke 2023," including TOAST etiological/pathogenic subtypes: large-artery atherosclerosis (LAA), cardioembolism (CE), small-artery occlusion (SAO), stroke of other determined etiology (SOE), and stroke of undetermined etiology (SUE)).
• Acute onset, with symptoms occurring within 72 hours and being the first episode.
• Voluntary participation with signed informed consent.

You may not qualify if:

• Patients with cerebrovascular diseases occurring within 72 hours.
• Pregnant or lactating patients.
• Other types of stroke, including hemorrhagic stroke, mixed stroke, and tumor-related stroke patients.
• Patients with coagulation disorders or other hematologic diseases.
• Patients with severe cardiovascular, pulmonary, or hepatic diseases.
• Renal dysfunction.
• Cancer patients.
• Patients with active gastric ulcers or gastric bleeding.
• Pregnant or lactating patients.

Sponsors & Collaborators

• Peking University Aerospace Center Hospital: lead

Study Sites (1)

Peking University Aerospace Center Hospital

Beijing, China

Location

MeSH Terms

Conditions

Ischemic Stroke; Stroke

Interventions

Clinical Protocols

Condition Hierarchy (Ancestors)

Cerebrovascular Disorders; Brain Diseases; Central Nervous System Diseases; Nervous System Diseases; Vascular Diseases; Cardiovascular Diseases

Intervention Hierarchy (Ancestors)

Therapeutics; Epidemiologic Study Characteristics; Health Care Evaluation Mechanisms; Quality of Health Care; Health Care Quality, Access, and Evaluation

Central Study Contacts

Xia Zhang, PhD

CONTACT

8618120175562; xzhangccmu@163.com

Study Design

• Study Type: observational
• Observational Model: COHORT
• Time Perspective: PROSPECTIVE
• Target Duration: 12 Months
• Sponsor Type: OTHER
• Responsible Party: PRINCIPAL INVESTIGATOR
• PI Title: Researcher

Study Record Dates

• First Submitted: November 25, 2025
• First Posted: December 8, 2025
• Study Start: January 25, 2026
• Primary Completion (Estimated): August 31, 2026
• Study Completion (Estimated): February 28, 2028
• Last Updated: December 8, 2025

Record last verified: 2025-11

Locations

CN (1)